Amadix secures Seed Investment

Nov. 17, 2011 - PRLog -- VALLADOLID – 16th November 2011. Amadix, a biotechnology company that develops innovative diagnostic tools that address unmet medical needs in Oncology, announces the successful closing of a seed investment round. The Company, founded in June 2010 as a spin-out of TCD Pharma, will use the funds to advance the development of its products that support the personalization of cancer treatment. The Company’s first products under development address unmet medical needs in the treatment of non-small cell lung cancer and colon cancer.
The round was led by Inveready Seed Capital SCR (“Inveready”), a Spanish venture capital fund that specializes in early stage investment, and by TCD Pharma (Amadix’s parent Company).

Ran Vigdor, CEO of Amadix said “We are very happy with the investment of Inveready, an investor with expertise in early stage investments and in-depth knowledge of the healthcare space. This investment is a vote of confidence in the Company’s potential.”
Inveready’s Managing Partner, Josep Maria Echarri i Torres, added “Amadix fits perfectly with our investment strategy. The Company has a strong technological base, an experienced management team and its products target large markets with significant growth potential. We are confident in its success.”

# # #

Amadix is a biotechnology Castilla y León company focused on the development and commercialization of innovative diagnostic tools that support personalized treatment in the field of Oncology.

The Company identifies, evaluates and in-licenses breakthrough discoveries in cancer diagnosis and develops them into marketable products that support physician´s treatment decisions and allow for personalized treatment.

Amadix is currently positioning itself as a Spain’s Partner of Choice for Oncology diagnostic and development opportunities. The aim of the Company is to build its pipeline through in-licensing of cutting edge technology.